Merial introduces SWIVAX?-MH, the first and only USDA approved swine vaccine administered by a needle-free delivery system exclusively from Merial.
Approved to aid in the reduction and control of respiratory disease due to Mycoplasma hyopneumoniae (M. hyo), this bacterin is specifically formulated to be administered exclusively with the DERMA-VAC? NF Transdermal Vaccination System, also new from Merial. SWIVAX-MH is prepared from inactivated cultures of M. hyo combined with an adjuvant. The vaccine cannot be used with a conventional needle and syringe.
Dr. Frank Milward, Merial Biological Research and Development, says there are many advantages to using transdermal delivery. "This mode of administration will allow for a targeted immune response, reduction of broken needles and increased worker safety," Dr. Milward says. "Also, less product is required for vaccination — 0.5 mL versus a typical dosage of 1.0 mL to 2.0 mL."
The DERMA-VAC NF Transdermal Vaccination System has been extensively field tested by Merial. The system has been shown to be reliable, simple to use, easy to maintain, animal welfare friendly and supportive of operator safety goals.
Merial will be demonstrating the DERMA-VAC NF Transdermal Vaccination System at their booth during the upcoming AASV Annual Meeting in Orlando. Be sure to stop by.